Molecular basis for the treatment of renal cell carcinoma |
| |
Authors: | Cristina Suárez Rafael Morales Eva Muñoz Jordi Rodón Claudia M Valverde Joan Carles |
| |
Institution: | (1) Department of Health and Human Services, Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive Bldg 10 Rm 1-5940, Bethesda, MD, 20892, USA |
| |
Abstract: | Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without
any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy),
with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated
with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the
tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab,
sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal
cancer treatment. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|